🚀 We’re hiring: Field Service Engineer II | PBS Biotech

Are you a hands-on technical problem solver who loves working with customers, solving complex equipment challenges, and supporting technology that helps advance the bioprocessing industry? PBS Biotech is looking for a Field Service Engineer to join our growing Commercial team in Camarillo, California.

At PBS Biotech, we develop innovative bioreactor solutions that support customers working at the forefront of cell therapy, biotech, and life sciences. From our headquarters in Camarillo, we partner with companies around the world to help bring next-generation therapies and innovations closer to reality.

In this customer-facing role, you’ll serve as a trusted technical resource for PBS bioreactor systems—supporting installations, IQ/OQ, preventative maintenance, troubleshooting, service documentation, and technical issue resolution. You’ll work closely with customers and cross-functional teams across Quality, Engineering, Manufacturing, and Commercial to ensure an excellent service experience and help translate field insights into meaningful product and process improvements.

This is a great opportunity for someone with experience in electromechanical equipment, bioprocess systems, field service, or technical support who enjoys travel, collaboration, and making an impact directly with customers.

✅ Hands-on technical service
✅ Customer-facing problem solving
✅ Bioreactor and bioprocessing technology
✅ Cross-functional collaboration
✅ Opportunity to support innovative life science solutions

If you’re excited about joining a mission-driven biotech company and helping customers succeed with advanced bioreactor technology, we’d love to hear from you.

📍 Location: Camarillo, CA
💰 Salary Range: $74,500 - $116,200
✈️ Travel: Domestic and international travel expected

About the Role:
The Service Engineer II serves as a technical liaison with customers, for performing technical services and support on the PBS bioreactor product as well as resolving any technical issues that may occur on the PBS bioreactor based on solid understanding of its design and components. This person should be proficient with diagnosing problems, replacing and upgrading hardware/ software components, and documenting services accurately while maintaining proper care and equipment of tools. This person is also responsible for helping to develop and maintain field service documents.

Primary Responsibilities

Perform scheduled on-site services, including IQ/OQ, system installation, preventative maintenance, troubleshooting, and resolution of PBS bioreactor hardware- and software-related issues through calls, emails, and on-site visits, ensuring timely execution, professional customer support, and accurate documentation. Issues beyond the scope of Service Engineer I may be escalated to this role.
Support customer complaint investigations and product feedback processes by gathering field data, documenting findings, communicating relevant customer input to internal teams, and collaborating with Quality, Engineering, and Manufacturing to identify root cause and corrective actions.
Serve as a backup internal resource for developing user requirements for product development and communicating applicable customer feedback to internal teams.
Develop, maintain, and contribute to field service documentation, including procedures, service reports, work instructions, technical documentation, and investigation reports, ensuring records are clear, accurate, and complete.
Provide necessary training for onboarding new Service Engineers.
Maintain and manage the tool sets assigned for bioreactor testing and field services.
Lead bioreactor configuration for all new units

Minimum Qualifications

The following are the minimum qualifications that an individual needs in order to successfully perform the duties and responsibilities of this position. Please note that the minimum qualifications may vary based upon the department size and/or geographic location.

Knowledge/ Experience

Bachelor’s degree preferred in Mechanical Engineering, Electrical Engineering, or a related technical discipline, with a minimum of 5+ years of relevant work experience with electromechanical equipment manufacturers.
In lieu of a Bachelor’s degree, 7+ years progressively responsible, directly related technical experience involving the installation, maintenance, troubleshooting, repair, and/or servicing of complex electromechanical equipment. Relevant technical education, certifications, or specialized training may also be considered as part of the equivalent experience.
Hands-on experience with bioprocess equipment, including a solid understanding of bioreactor functions, components, and operation.
Prior customer-facing field service or technical support experience with electromechanical equipment preferred.

Skills/ Abilities Pertinent to This Position

Strong interpersonal and customer service skills, with the ability to establish effective working relationships with customers and internal stakeholders.
Excellent written and verbal communication skills in English.
Willingness and ability to travel domestically and internationally approximately 25% of the time, with additional travel as required based on business needs.
Ability to work independently with minimal supervision and collaboratively within a multi-functional team.

Physical Demands

In general, the following physical demands are representative of those that must be met by an employee to successfully perform the essential functions of this job. Reasonable accommodations may be made to allow differently-abled individuals to perform the essential functions of the job.

Must be able to see, hear, speak, and write clearly in order to communicate with employees and/or vendors. Manual dexterity is required for occasional reaching, lifting of small objects, and operating manufacturing equipment. Must be able to lift various weights as needed to meet job requirements.

Work Environment

In general, the following conditions of the work environment are representative of those that an employee encounters while performing the essential functions of this job. Reasonable accommodations may be made to allow differently-abled individuals to perform the essential functions of the job within the environment.

May be required to enter GMP or controlled manufacturing areas and follow applicable gowning, hygiene, and safety procedures for long periods of time.

Occasionally exposed to moving mechanical parts, fumes, machine lubricants, airborne particles, vibration, risk of electrical shock, and high noise levels while in the manufacturing plant. Personal protective equipment for vision and hearing is used in the plant.

About the company

PBS Biotech designs, manufactures, and sells single-use bioreactor systems and offers process development and technical support for cell therapy manufacturing. Its core Vertical-Wheel technology provides gentle, homogeneous mixing suitable for shear-sensitive cells like iPSCs and MSCs, enabling scalable suspension or microcarrier culture from research to clinical production. The company operates a B2B model, supplying equipment and disposable components along with customized process development services to academic, biotech, and pharmaceutical customers. With an ISO 9001:2015 certified facility and plans to scale to over $100 million in annual revenue, PBS Biotech aims to expand manufacturing capacity to support commercialization of cell therapies.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$49M

Headquarters

Camarillo, California

Founded

2006

Get referred to PBS Biotech

See people who can refer or advise you

Simplify's Take

What believers are saying

PBS raised $17 million in January 2025 and expanded manufacturing for $100 million revenue.
MiniPRO expanded availability in August 2026, signaling product-market pull for process-development customers.
PBS won Life Sciences Review's 2026 award and deepened partnerships with Rockwell and denovoMATRIX.

What critics are saying

MiniPRO shipping depends on fragile cell-therapy capital spending and customer adoption in 2026.
Customer concentration in cell therapy ties revenue to biotech funding cycles and clinical setbacks.
If Rockwell or larger automation vendors replicate Vertical-Wheel economics, PBS loses its wedge.

What makes PBS Biotech unique

Vertical-Wheel bioreactors create low-shear mixing for iPSCs, MSCs, and NK cells.
MiniPRO runs 24 parallel vessels with Rockwell FactoryTalk, linking development to GMP.
Martin Simonetti, Brian Lee, and ex-Thermo Fisher operators give PBS deep execution credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

PR Newswire

Sep 29th, 2026

PBS Biotech accelerates cell therapy development with Rockwell Automation technology

PBS Biotech has integrated Rockwell Automation technology into its MiniPRO bioreactor platform to accelerate cell therapy development. The system features up to 24 independently controlled bioreactors and uses FactoryTalk software to deliver real-time process control. The platform addresses industry challenges including low-throughput workflows and non-standardised environments that slow progress in Advanced Therapeutic Medicinal Products development. By embedding industrial-grade automation during product development, the system enables seamless progression to clinical and commercial manufacturing. The Advanced Regenerative Manufacturing Institute adopted the platform, noting that integration with existing control systems is streamlined due to Rockwell's standardised technology. PBS Biotech has demonstrated consistent process performance between the MiniPRO and its larger-scale Vertical-Wheel bioreactors, supporting predictable transfer into Good Manufacturing Practice settings.

Business Wire

Sep 16th, 2026

PBS Biotech Raises $10M to Provide Scale-Up Manufacturing Solutions for Cell Therapies

Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the c...

PR Newswire

Jul 21st, 2026

PBS Biotech wins 2026 cell Products Development of the Year award.

PBS Biotech wins 2026 cell Products Development of the Year award. Jul 21, 2026, 07:00 ET Recognition Highlights Company's Leadership in Advancing Linearly Scalable, Advanced Cell Therapy Manufacturing CAMARILLO, Calif., July 21, 2026 /PRNewswire/ - PBS Biotech, a leading developer of innovative single-use bioreactor technologies for cell therapy manufacturing, today announced it has been named Cell Therapy Products Development of the Year 2026 by Life Sciences Review. The company was also recognized among the publication's Top Companies in Cell and Gene Therapy, underscoring PBS Biotech's growing impact on the future of advanced therapeutic manufacturing. The recognition reflects PBS Biotech's continued commitment to helping cell therapy developers overcome one of the industry's greatest challenges: reliably scaling manufacturing while preserving cell quality and function. Through its patented Vertical-Wheel(R) bioreactor technology, PBS Biotech enables gentle, low-shear cell culture that supports the expansion and differentiation of a broad range of sensitive cell types, from early process development through commercial manufacturing. "As cell therapies continue to transform medicine, manufacturers need technologies that eliminate the traditional tradeoff between scalability and cell quality," said Martin Simonetti, Chief Executive Officer of PBS Biotech. "We're honored that Life Sciences Review has recognized our team's dedication to advancing manufacturing solutions that help bring life-changing therapies to patients faster." Unlike conventional stirred-tank bioreactors, PBS Biotech's Vertical-Wheel platform was specifically engineered to create homogeneous mixing with exceptionally low shear forces, providing an environment well suited for sensitive cell types including induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), T cells, NK cells, CAR-T, CAR-NK, and pancreatic islet cells. The technology offers linear scalability from research through manufacturing, enabling customers to simplify process development and accelerate technology transfer. In its feature, Life Sciences Review highlighted PBS Biotech's customer-centric approach, commitment to innovation, and expanding collaborations across the cell and gene therapy ecosystem. The publication also recognized the company's role in helping developers address critical manufacturing bottlenecks as more cell therapies advance toward commercialization. "This recognition belongs to our employees, customers, collaborators, and partners who continue pushing the boundaries of regenerative medicine," Simonetti added. "Together, we're building the manufacturing foundation that will enable the next generation of cell therapies to reach more patients around the world." As demand for scalable, robust manufacturing platforms continues to grow, PBS Biotech remains focused on expanding its technology portfolio, supporting customer success, and advancing manufacturing solutions that accelerate the commercialization of transformative cell therapies. About PBS Biotech PBS Biotech is a biotechnology company dedicated to advancing the manufacture of next-generation cell therapies through innovative bioreactor technologies. Its patented Vertical-Wheel(R) bioreactor platform delivers gentle, low-shear mixing with scalable performance to support process development, clinical manufacturing, and commercial production. PBS Biotech partners with leading biotechnology companies, CDMOs, and academic institutions worldwide to accelerate the development and commercialization of life-changing cell therapies. About Forward-Looking Statements This press release contains forward-looking statements regarding PBS Biotech's future plans, expectations, and business outlook, including statements related to the development, adoption, and commercialization of cell therapy manufacturing technologies. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. PBS Biotech undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise. Media Contact SOURCE PBS Biotech Inc.

FinSMEs

Jan 6th, 2025

PBS Biotech Raises $17M in Growth Funding

PBS Biotech raises $17M in Growth funding.

Pulse 2.0